Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Lenalidomide Maintenance in Multiple Myeloma
NCT07485647Phase 2Recruiting
- Sponsor
- Arcellx
- Start
- Apr 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Arcellx. Started Apr 2026; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07485647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485647.